A product used for the therapy of coccidiosis in piglets, lambs and dairy calves has now been licensed to be used in beef calves.
The one toltrazuril therapy licensed for coccidiosis in bull beef and suckler calves within the UK, Baycox Multi from Bayer allows beef producers to deal with and management one of the crucial widespread causes of scour.
Fraser Claughton, Bayer UK/IE industrial supervisor, stated: “The one-dose therapy is already obtainable to be used in dairy calves and has been confirmed in trials as an efficient therapy in beef calves.
“Early preventive management in affected calves – metaphyalctic use – with Baycox Multi, resulted in Chianina beef calves averaging 11kg heavier at 40 weeks post-treatment, in comparison with these given diclazuril.”
Baycox Multi has additionally been confirmed to considerably scale back the shedding of oocysts within the animal’s faeces, serving to restrict the unfold of illness.
The anti-coccidial drug is run orally and appropriate to be used in beef calves below 150kg.